Literature DB >> 21392724

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number.

James D Otvos1, Samia Mora, Irina Shalaurova, Philip Greenland, Rachel H Mackey, David C Goff.   

Abstract

BACKGROUND: The amount of cholesterol per low-density lipoprotein (LDL) particle is variable and related in part to particle size, with smaller particles carrying less cholesterol. This variability causes concentrations of LDL cholesterol (LDL-C) and LDL particles (LDL-P) to be discordant in many individuals.
METHODS: LDL-P measured by nuclear magnetic resonance spectroscopy, calculated LDL-C, and carotid intima-media thickness (IMT) were assessed at baseline in the Multi-Ethnic Study of Atherosclerosis, a community-based cohort of 6814 persons free of clinical cardiovascular disease (CVD) at entry and followed for CVD events (n = 319 during 5.5-year follow-up). Discordance, defined as values of LDL-P and LDL-C differing by ≥ 12 percentile units to give equal-sized concordant and discordant subgroups, was related to CVD events and to carotid IMT in models predicting outcomes for a 1 SD difference in LDL-C or LDL-P, adjusted for age, gender, and race.
RESULTS: LDL-C and LDL-P were associated with incident CVD overall: hazard ratios (HR 1.20, 95% CI [CI] 1.08-1.34; and 1.32, 95% CI 1.19-1.47, respectively, but for those with discordant levels, only LDL-P was associated with incident CVD (HR 1.45, 95% CI 1.19-1.78; LDL-C HR 1.07, 95% CI 0.88-1.30). IMT also tracked with LDL-P rather than LDL-C, ie, adjusted mean IMT of 958, 932, and 917 microm in the LDL-P > LDL-C discordant, concordant, and LDL-P < LDL-C discordant subgroups, respectively, with the difference persisting after adjustment for LDL-C (P = .002) but not LDL-P (P = .60).
CONCLUSIONS: For individuals with discordant LDL-C and LDL-P levels, the LDL-attributable atherosclerotic risk is better indicated by LDL-P.
Copyright © 2011 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392724      PMCID: PMC3070150          DOI: 10.1016/j.jacl.2011.02.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  29 in total

Review 1.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Authors:  Elias J Jeyarajah; William C Cromwell; James D Otvos
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

Review 2.  Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.

Authors:  Ira Tabas; Kevin Jon Williams; Jan Borén
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

Review 3.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Authors:  John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2008-04-15       Impact factor: 24.094

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Effects of the amount and intensity of exercise on plasma lipoproteins.

Authors:  William E Kraus; Joseph A Houmard; Brian D Duscha; Kenneth J Knetzger; Michelle B Wharton; Jennifer S McCartney; Connie W Bales; Sarah Henes; Gregory P Samsa; James D Otvos; Krishnaji R Kulkarni; Cris A Slentz
Journal:  N Engl J Med       Date:  2002-11-07       Impact factor: 91.245

Review 6.  Metabolic origins and clinical significance of LDL heterogeneity.

Authors:  Kaspar K Berneis; Ronald M Krauss
Journal:  J Lipid Res       Date:  2002-09       Impact factor: 5.922

7.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

8.  Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.

Authors:  Allan D Sniderman; Annie C St-Pierre; Bernard Cantin; Gilles R Dagenais; Jean-Pierre Després; Benoît Lamarche
Journal:  Am J Cardiol       Date:  2003-05-15       Impact factor: 2.778

9.  Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group.

Authors:  D H O'Leary; J F Polak; R A Kronmal; P J Savage; N O Borhani; S J Kittner; R Tracy; J M Gardin; T R Price; C D Furberg
Journal:  Stroke       Date:  1996-02       Impact factor: 7.914

10.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

View more
  100 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

2.  Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome.

Authors:  Anuja Dokras; Martin Playford; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; David B Sarwer; Kelly C Allison; Christos Coutifaris; Nehal Mehta; Richard S Legro
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-09       Impact factor: 3.478

3.  [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease].

Authors:  Si Chen; Jin-Zhen Zhao; Jing Hu; Zhi-Gang Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

4.  Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy.

Authors:  Roger Mallol; Núria Amigó; Miguel A Rodríguez; Mercedes Heras; Maria Vinaixa; Núria Plana; Edmond Rock; Josep Ribalta; Oscar Yanes; Lluís Masana; Xavier Correig
Journal:  J Lipid Res       Date:  2015-01-07       Impact factor: 5.922

Review 5.  Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes.

Authors:  Anastasia-Stefania Alexopoulos; Ali Qamar; Kathryn Hutchins; Matthew J Crowley; Bryan C Batch; John R Guyton
Journal:  Curr Diab Rep       Date:  2019-02-26       Impact factor: 4.810

6.  Lipoprotein Heterogeneity Early in Pregnancy and Preterm Birth.

Authors:  Janet M Catov; Rachel H Mackey; Christina M Scifres; Marnie Bertolet; Hyagriv N Simhan
Journal:  Am J Perinatol       Date:  2017-05-22       Impact factor: 1.862

7.  Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study.

Authors:  Ron C Hoogeveen; John W Gaubatz; Wensheng Sun; Rhiannon C Dodge; Jacy R Crosby; Jennifer Jiang; David Couper; Salim S Virani; Sekar Kathiresan; Eric Boerwinkle; Christie M Ballantyne
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-20       Impact factor: 8.311

8.  Reduction in dietary trans fat intake is associated with decreased LDL particle number in a primary prevention population.

Authors:  M Garshick; H Mochari-Greenberger; L Mosca
Journal:  Nutr Metab Cardiovasc Dis       Date:  2013-10-05       Impact factor: 4.222

9.  Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.

Authors:  Ying Zhang; Alicia J Jenkins; Arpita Basu; Julie A Stoner; Maria F Lopes-Virella; Richard L Klein; Timothy J Lyons
Journal:  J Lipid Res       Date:  2015-12-09       Impact factor: 5.922

10.  Vasomotor symptoms and lipids/lipoprotein subclass metrics in midlife women: Does level of endogenous estradiol matter? The SWAN HDL Ancillary Study.

Authors:  Alexis Nasr; Karen A Matthews; Maria M Brooks; Daniel S McConnell; Trevor J Orchard; Jeffrey Billheimer; Daniel J Rader; Samar R El Khoudary
Journal:  J Clin Lipidol       Date:  2020-07-08       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.